Transgene's TG4010 NSCLC Development Program to Include Two Companion Tests

Transgene plans to use the tests from Ventana and Beckman Coulter to analyze which subpopulations of patients with advanced NSCLC will likely respond best to the MVA-MUC1-IL2 immunotherapeutic in combination with first-line therapy.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.